Who is sponsoring NCT03399513?

NCT03399513 is sponsored by University Hospital Muenster.

What drugs are being tested in NCT03399513?

Interventions in NCT03399513: Ibrutinib Oral Capsule [Imbruvica], R-CHOEP chemotherapy.

What condition does NCT03399513 study?

NCT03399513 studies Diffuse Large B Cell Lymphoma.

Is NCT03399513 still recruiting?

NCT03399513 is currently completed. Last updated 5 January 2024.

Last reviewed 2024-01-05 · How we verify

NCT03399513: R-CHOEP-brut

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

Completed Phase 2 Last updated 5 January 2024

What this trial tests

Phase 2 trial testing Ibrutinib Oral Capsule [Imbruvica] in Diffuse Large B Cell Lymphoma in 40 participants. Completed in 23 December 2023.

Timeline

3 May 2018

Primary endpoint
23 December 2023

23 December 2023

Quick facts

Lead sponsor	University Hospital Muenster
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	3 May 2018
Primary completion	23 December 2023
Estimated completion	23 December 2023
Sites	12 locations across Germany

Drugs / interventions tested

Ibrutinib Oral Capsule [Imbruvica] — full drug profile →
R-CHOEP chemotherapy — full drug profile →

Conditions studied

Diffuse Large B Cell Lymphoma — all drugs for Diffuse Large B Cell Lymphoma →

Sponsor

University Hospital Muenster

Who can join

Adults 18 to 60, any sex, with Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate if treatment results obtained with R-CHOEP in young high-risk patients with diffuse large B-cell lymphoma can be further improved by the addition of ibrutinib to this regimen.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.
Miao Y, Medeiros LJ, Xu-Monette ZY, Li J, et al · · 2019 · cited 39× · PMID 30881917 · DOI 10.3389/fonc.2019.00107
Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma.
Wang S, Clapper E, Tonissen KF, Di Trapani G. · · 2023 · cited 4× · PMID 36830087 · DOI 10.3390/antiox12020529

Verify or expand the search:

Other recruiting trials for Diffuse Large B Cell Lymphoma

Currently open trials in the same condition.

NCT06687772 — CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · Phase 2 · recruiting
NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
NCT06552572 — Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy · Phase 2 · active not recruiting
NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting

Other University Hospital Muenster trials

Trials by the same sponsor.

NCT07414498 — MICRO-SURG: Subgingival Microbiome in Peri-Implantitis, Regenerative, and Resective Periodontal Surgery · NA · not yet recruiting
NCT06999174 — Multiparametric MRI for Characterization of Hepatocellular Carcinoma · recruiting
NCT06980740 — Video-Tumorboard PLUS · recruiting
NCT06648733 — Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care · NA · recruiting
NCT06464302 — Investigation of the Effect of Age and Injury Severity on Short-term Intra-hospital Outcomes After Surgical Stabilized R · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03399513 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Muenster
Last refreshed: 5 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03399513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing